Novo Nordisk B

Explore how Novo Nordisk’s new approvals for Wegovy in India and Extensior in South Africa boost access to GLP‑1 treatments for diabetes and NAFLD, driving growth and affordability.

Novo Nordisk’s EU approval of Wegovy oral tablet boosts market access, 5‑10 % sales lift, and strengthens its GLP‑1 obesity lead—an insider look at strategy and growth.

Wegovy’s EU tablet launch boosts Novo Nordisk’s obesity portfolio, driving €1.2 bn revenue, higher adherence, and cost‑saving reimbursement prospects.

Explore how Novo Nordisk’s supplier‑discount strategy reshapes pharma pricing, value‑based reimbursement, and supply‑chain resilience, while safeguarding patient outcomes.

Goldman Sachs lifts Novo Nordisk’s target to DKK 310, citing robust GLP‑1 sales and a strong pipeline that fuels a cautiously optimistic long‑term outlook.

Discover how Novo Nordisk is targeting U.S. Medicare patients with a new oral weight‑loss pill, beating rivals and expanding into China.

Discover how Novo Nordisk’s legal wins, GLP‑1 dominance, and strategic pipeline keep it ahead in obesity and diabetes markets—learn why analysts are buying.

Novo Nordisk faces a cyber‑extortion claim yet its obesity drugs stay strong—see how the breach impacts data security, FDA scrutiny, and Wegovy’s China launch.

Discover how Novo Nordisk’s cyber‑security, UK Wegovy approval and Czech hub reshape pharma resilience, growth, and market strategy.

Investigative analysis of Novo Nordisk’s cyber‑security breach and UK Wegovy® approval, revealing data‑privacy risks, market gains, and strategic risk‑management insights.